Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 15/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3209241 | 0.83 | CA12 (0.60) | MEN1KMT2A | |
| SCHEMBL3215854 | 0.82 | TDP1 (0.56) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL3558312 | 0.79 | MEN1 (0.63) | TBXAS1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL30208757 | 0.79 | MEN1 (0.63) | TBXAS1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL7670526 | 0.77 | CHRNA7 (0.49) | TBXAS1 | |
| SCHEMBL27713238 | 0.77 | TDP1 (0.70) | TBXAS1 | |
| SCHEMBL7423225 | 0.76 | KDM4E (0.56) | TBXAS1MEN1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1238218 | 0.75 | TDP1 (0.68) | TBXAS1 | |
| SCHEMBL25784651 | 0.73 | HDAC2 (0.61) | TBXAS1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL25179537 | 0.73 | TBXAS1 (0.62) | TBXAS1MEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041892-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2010-02-18 | — | — | US | disclosed |
| US-20090270631-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2009-10-29 | — | — | US | disclosed |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270631-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | TBXAS1 1788/4885MEN1 3927/4885NPC1 1683/4885 |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | FABP4, SLC5A1, SLC5A2 | TBXAS1 1568/4885MEN1 3517/4885NPC1 1377/4885 |
| US-20100041892-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | TBXAS1 1788/4885MEN1 3927/4885NPC1 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.